Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-response study of MEDI7352 in painful osteoarthritis of the knee
2020-003797-51Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2020
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MEDI7352 in knee osteoarthritis (OA) (4 arms), sponsored by AstraZeneca. Primary endpoint: Change in the weekly average of daily NRS pain scores from baseline to Week 12. Started Dec 2020; status: completed.
02
Drugs
MEDI7352
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on 2020-003797-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003797-51.